drugset / Trial / NCT06025032
a Study in Subjects With Otoferlin Mutation-related Hearing Loss Using RNA Base-eDiting Therapy(SOUND)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to determine whether HG205 as CRISPR/Cas13 RNA base-editing therapy is safe and effective for the treatment of hearing loss caused by p.Q829X mutation in OTOF gene.
Timeline
- Start
- 2023-03-30
- Primary completion
- 2025-04-08
- Completion
- 2025-04-08
Outcome
Outcome not reported
Stopped: “Huidagene stopped this program as lack of patients in China”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HG205 | CRISPR / gene editing | — | Other |